#AHA22 will be remembered for the science and the interpersonal connections. As Vice Chair of the Committee on Scientific Sessions Programming, it was rewarding for me to see the culmination of hard work over this past year by so many thought leaders and AHA staff. There were more than 4,000 scientific abstracts presented and 700 sessions convened at the meeting, whose content covered the spectrum of basic, clinical, and population science. Numerous UT Southwestern faculty and fellows participated in abstract presentations, in session moderation, and as invited presenters discussing the latest scientific breakthroughs. Of course, the Late-Breaking Science sessions garnered the most attention. This year, there was a 40% increase in Late-Breaking submissions, resulting in a record nine sessions inclusive of 35 trials. These studies have immediate impact on clinical practice. For example, the TRANSFORM-HF trial provides flexibility for diuretic use in patients with heart failure, the PROMINENT trial will likely end the use of fibrates for cardiovascular risk reduction, and the EMPA-KIDNEY trial expands the use of SGLT2 inhibitors in those with chronic kidney disease. #AHA22 also offered new clinical sessions, including an exciting collaboration between the Transcatheter Cardiovascular Therapeutics (TCT) conference and AHA for interventional case and health technology programming, as well as a greatly expanded category for clinical case abstracts.